Pharmacogenetics of Antiplatelet Therapy

Overview

Journal Annu Rev Pharmacol Toxicol

Publisher Annual Reviews

Specialties Pharmacology
Toxicology

Date 2022 Aug 1

PMID 35914768

Authors

Matteo Castrichini

Jasmine A Luzum

Naveen Pereira

Affiliations

Soon will be listed here.

Abstract

Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.

Citing Articles

Association of c.681G>A (rs4244285) Loss-of-function Allele with Cardiovascular Disease Risk in the Kosovo Population.

Elshani N, Ukella K, Staninova S, Naumovska Z, Kurshumliu M, Gorani D Balkan J Med Genet. 2025; 27(2):77-85.

PMID: 40070858 PMC: 11892937. DOI: 10.2478/bjmg-2024-0015.

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.

Huxley S, Moriarty J, Hlatky M, Lennon R, Bailey K, Bell M Pharmacogenomics J. 2024; 24(6):32.

PMID: 39379363 DOI: 10.1038/s41397-024-00353-y.

The polygenic implication of clopidogrel responsiveness: Insights from platelet reactivity analysis and next-generation sequencing.

Echeverria O, Angulo-Aguado M, Vela R, Calderon-Ospina C, Parra K, Contreras N PLoS One. 2024; 19(7):e0306445.

PMID: 38991024 PMC: 11239111. DOI: 10.1371/journal.pone.0306445.

Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.

Pereira N, Cresci S, Angiolillo D, Batchelor W, Capers 4th Q, Cavallari L Circulation. 2024; 150(6):e129-e150.

PMID: 38899464 PMC: 11300169. DOI: 10.1161/CIR.0000000000001257.

From genes to drugs: and pharmacogenetics in clinical practice.

Shubbar Q, Alchakee A, Issa K, Adi A, Shorbagi A, Saber-Ayad M Front Pharmacol. 2024; 15:1326776.

PMID: 38420192 PMC: 10899532. DOI: 10.3389/fphar.2024.1326776.

References

Rasmussen-Torvik L, Stallings S, Gordon A, Almoguera B, Basford M, Bielinski S . Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014; 96(4):482-9. PMC: 4169732. DOI: 10.1038/clpt.2014.137. View

Kelly R, Close S, Farid N, Winters K, Shen L, Natanegara F . Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol. 2011; 73(1):93-105. PMC: 3248259. DOI: 10.1111/j.1365-2125.2011.04049.x. View

Luzum J, Luzum M . Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Per Med. 2018; 13(2):119-127. PMC: 5907693. DOI: 10.2217/pme.15.57. View

Price M, Murray S, Angiolillo D, Lillie E, Smith E, Tisch R . Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012; 59(22):1928-37. DOI: 10.1016/j.jacc.2011.11.068. View

Gower M, Ratner L, Williams A, Rossi J, Stouffer G, Lee C . Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. Pharmgenomics Pers Med. 2020; 13:239-252. PMC: 7419635. DOI: 10.2147/PGPM.S231475. View

Schror K . Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med. 1999; 3(3):247-51. DOI: 10.1177/1358836X9800300312. View

Tornio A, Flynn R, Morant S, Velten E, Palmer C, MacDonald T . Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records. Clin Pharmacol Ther. 2017; 103(2):281-286. PMC: 5813097. DOI: 10.1002/cpt.780. View

Faraday N, Becker D, Becker L . Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics. 2007; 8(10):1413-25. DOI: 10.2217/14622416.8.10.1413. View

Abul-Husn N, Obeng A, Sanderson S, Gottesman O, Scott S . Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med. 2014; 7:227-40. PMC: 4157398. DOI: 10.2147/PGPM.S48887. View

10.

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update.... Circulation. 2016; 134(10):e123-55. DOI: 10.1161/CIR.0000000000000404. View

11.

Li C, Jia W, Li J, Li F, Ma J, Zhou L . Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients. BMC Neurol. 2021; 21(1):104. PMC: 7941922. DOI: 10.1186/s12883-021-02127-6. View

12.

Linskey D, Linskey D, McLeod H, Luzum J . The need to shift pharmacogenetic research from candidate gene to genome-wide association studies. Pharmacogenomics. 2021; 22(17):1143-1150. PMC: 8738979. DOI: 10.2217/pgs-2021-0108. View

13.

Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D . Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2017; 11(2):181-191. PMC: 5775044. DOI: 10.1016/j.jcin.2017.07.022. View

14.

Storey R, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H . Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009; 20(5):341-8. DOI: 10.1080/09537100903075324. View

15.

Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp C . Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013; 28(8):2116-22. DOI: 10.1093/ndt/gft103. View

16.

Wang Y, Chen W, Lin Y, Meng X, Chen G, Wang Z . Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ. 2019; 365:l2211. PMC: 6549283. DOI: 10.1136/bmj.l2211. View

17.

Kazi D, Garber A, Shah R, Dudley R, Mell M, Rhee C . Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014; 160(4):221-32. DOI: 10.7326/M13-1999. View

18.

Erlinge D, James S, Duvvuru S, Jakubowski J, Wagner H, Varenhorst C . Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost. 2014; 111(5):943-50. DOI: 10.1160/TH13-09-0767. View

19.

Handa Y, Fukushima S, Yo S, Osawa M, Murao T, Handa O . A novel gene associated with small bowel bleeding in patients taking low-dose aspirin. Dig Liver Dis. 2021; 53(7):841-845. DOI: 10.1016/j.dld.2021.04.038. View

20.

Sistonen J, Fuselli S, Palo J, Chauhan N, Padh H, Sajantila A . Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009; 19(2):170-9. DOI: 10.1097/FPC.0b013e32831ebb30. View